Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.74% | -1.46% | 11.00% | 97.65% | 290.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.06% | 14.28% | 51.42% | -66.34% | 192.72% |
| Operating Income | -1.06% | -14.28% | -51.42% | 66.34% | -192.72% |
| Income Before Tax | -1.45% | -6.47% | 54.61% | 68.77% | -100.88% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.45% | -6.47% | 54.61% | 68.77% | -100.88% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.45% | -6.47% | 54.61% | 68.77% | -100.88% |
| EBIT | -1.06% | -14.28% | -51.42% | 66.34% | -192.72% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 20.27% | 81.81% | 96.84% | 97.74% | 85.76% |
| Normalized Basic EPS | 20.27% | 81.81% | 96.84% | 97.74% | 85.76% |
| EPS Diluted | 20.27% | 81.81% | 96.84% | 97.74% | 85.76% |
| Normalized Diluted EPS | 20.27% | 81.81% | 96.84% | 97.74% | 85.76% |
| Average Basic Shares Outstanding | 27.25% | 485.32% | 1,337.96% | 1,282.95% | 1,310.67% |
| Average Diluted Shares Outstanding | 27.25% | 485.32% | 1,337.96% | 1,282.95% | 1,310.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |